Drug Database · Clinicians

Moxifloxacin

Brands (59) Avelox, Moxidin, 4-Quin…Show all

Antibacterial (fluoroquinolones); Anti-infectives (fluoroquinolones); and others PH FDA category

Rx · Prescription drug73 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 12053b08-7e66-c6f3-e063-6394a90a9cd9, version date January 22, 2026 (VIGAMOX · Harrow Eye, LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • VIGAMOX ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE VIGAMOX ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. VIGAMOX is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species*, Micrococcus luteus*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri*, Streptococcus pneumoniae, Streptococcus viridans group, Acinetobacter lwoffii*, Haemophilus influenzae, Haemophilus parainfluenzae*, Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections.

(1)

Contraindications

4 CONTRAINDICATIONS VIGAMOX is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication. VIGAMOX is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

2 DOSAGE AND ADMINISTRATION Instill one drop in the affected eye 3 times a day for 7 days. VIGAMOX is for topical ophthalmic use. Instill one drop in the affected eye 3 times a day for 7 days. (2)

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of VIGAMOX have been established in all ages. Use of VIGAMOX is supported by evidence from adequate and well controlled studies of VIGAMOX in adults, children, and neonates [see Clinical Studies (14)]. There is no evidence that the ophthalmic administration of VIGAMOX has any effect on weight bearing joints, even though oral administration of some quinolones has been shown to cause arthropathy in immature animals.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger patients.

Dosage forms

Philippines

  • Ophthalmic solution: 5 mg/mL
  • Film-coated tablet: 400 mg
  • Sterile ophthalmic solution: 5 mg per mL, 5 mg/mL
  • Solution for iv infusion: 400 mg/100 mL, 400 mg/250 mL
  • ) solution for intravenous infusion: 1.6 mg/mL (400 mg/250 mL
  • Sterile ophthalmic ointment: 5 mg/g
  • Tablet: 400 mg
  • W/v) ophthalmic solution: 5 mg/mL (0.5 %
  • ) solution for injection: 1.6 mg/mL (400 mg/250 mL
  • Film-coated caplet: 400 mg

and 5 more forms; see the products table.

Registered products in the Philippines

73 products registered with the Food and Drug Administration (FDA) Philippines list Moxifloxacin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Moxifloxcin (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products73
Philippine FDA-registered products for Moxifloxacin
Package insert
4-QuinMoxifloxacin (as Hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic Solution5 mL LDPE bottle with nozzle and cap (Box of 1's)
Rx
Makcur Laboratories LimitedIndia
Importer: Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Limited
DR-XY46546
Apr 1, 2027
4-QuinMoxifloxacin (as Hydrochloride)
5mg/ml (0.5% w/v) Ophthalmic Solution5ml LDPE Bottle with Nozzle and Cap (Box of 1's)
Rx
Makcur Laboratories Ltd.India
Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Ltd.
DRP-11229
Apr 1, 2027
Agua MoxiMoxifloxacin (as Hydrochloride)
5mg/mL (0.5 % w/v) Sterile Ophthalmic Solution5 mL white opaque LDPE bottle, white opaque LDPE nozzle and white opaque HDPE cap (Box of 1's)
Rx
Indiana Ophthalmics LLPIndia
Agua Visions TradingImporter: Medinova Pharmaceutical, Inc.
DRP-13587-02
Mar 14, 2028
AmoxifloxMoxifloxacin (as hydrochloride)
5 mg/mL Ophthalmic Solution (Eye Drops)LDPE Bottle x 5 mL (Box of 1's)
Rx
ASHFORD PHARMACEUTICAL LABORATORIES, INC.Philippines
Trader: SENSOMED PHILS., INC.
DR-XY42705
Oct 2, 2028
AuromoxMoxifloxacin (as hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drop)2 mL Type I Borosilicate Flint Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Flip- Off Seal Cap (Net content: 1 mL) (Box of 5's)
Rx
AurolabIndia
Brady Pharma, Inc.
DR-XY48572
Jan 18, 2028
AveloxMoxifloxacin (as hydrochloride)
400 mg Film-Coated TabletAlu/Alu blister pack x 5's (Box of 10's)
Rx
Bayer Healthcare Manufacturing S.r.l.Italy
Bayer Philippines, Inc.
DR-XY47545
Nov 18, 2031
AveloxMoxifloxacin (as Hydrochloride)
400 mg TabletAlu/Alu Blister Pack x 5's (Box of 20's)
Rx
Bayer AGGermany
Bayer Philippines, Inc.
DR-XY25608
Mar 30, 2029
AveloxMoxifloxacin (Hydrochloride)
400 mg/ 250 mL Solution For IV Infusion250 mL Type II colorless glass bottle closed with gray chlorobutyl rubber stopper and aluminum polypropylene flip off seal (Box of 1's)
Rx
Fresenius Kabi Italia S.R.L.Italy
Importer: Bayer Philippines, Inc.
DR-XY47541
Nov 18, 2026
AxqinMoxifloxacin (as hydrochloride)
1.6 mg/mL (400 mg/250 mL) Solution for Intravenous InfusionLDPE Bottle with White Dust Cap x 250 mL (Blox of 1's)
Rx
AXA Parenterals LimitedIndia
Brady Pharma Inc.
DRP-9558
Apr 30, 2031
DemoxifMoxifloxacin (as hydrochloride)
400 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 7's (Box of 7's)
Rx
Deva Holding A.S.Turkey
Endure Medical, Inc.
DR-XY49057
Apr 19, 2029
DespimoxMoxifloxacin (as hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic SolutionWhite Opaque Low Density Polyethylene (LDPE) Vial x 10 mL (Box of 1's)
Rx
Scott-Edil Pharmacia LimitedIndia
Despina Pharma Inc.
DRP-17922
Apr 13, 2031
EloximMoxifloxacin (as hydrochloride)
5 mg per mL (0.5% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE Plastic Bottle x 5 mL with Natural LDPE Nozzle and White HDPE Cap in 5 mL (net content) (Box of 1’s)
Rx
Indoco Remedies LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-7692-03
Feb 7, 2028
FlorqinMoxifloxacin (as Hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)5 mL Dropper Bottle with Plug and Cap (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Despina Pharma Inc.
DRP-15395
Jul 3, 2029
Floxquin 400Moxifloxacin (as hydrochloride)
400mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Lee Pharma LimitedIndia
Saifen Drugs Philippines Inc.
DRP-16548
Apr 22, 2030
FloxsafeMoxifloxacin (as hydrochloride)
400 mg Film-Coated TabletAlu/ Clear PVC/PVDC Bister pack x 10's (Box of 30's)
Rx
MSN Laboratories Private Limited (Formulations Division)India
Biocare Lifesciences Inc.
DR-3068
Jun 17, 2031
GoxifloxMoxifloxacin (as hydrochloride)
400 mg/ 100 mL Solution for IV InfusionLDPE Bottle with Helmet Cap on Topped Bagged in Polypouch x 100 mL (Box of 1's)
Rx
BML Parenteral DrugsIndia
Go Healthcare Pharmaceutical DistributionImporter: Triple Tact Import & Export Corp.
DRP-15418-01
Jul 5, 2029
IkshamoxMoxifloxacin (as hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic Solution5 mL LDPE Bottle with nozzle and cap (Box of 1's)
Rx
Makcur Laboratories LimitedIndia
Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp.
DRP-13578-02
Mar 13, 2028
ImoxMoxifloxacin (as hydrochloride)
5 mg/mL (0.5%w/v) Ophthalmic SolutionPolypropylene container with pilfer proof polypropylene cap x 5 mL (Box of 1's)
Rx
The ACME Laboratories Ltd.Bangladesh
Euro Generics International Phils., Inc.
DR-XY46085
Oct 19, 2027
JoyloxinMoxifloxacin
400 mg/250 mL Solution for IV InfusionUSP Type I Borosilicate Glass Vial with Gray Color Rubber Closure and Aluminum Flip-off Cap x 250 mL
Rx
Korea United Pharm. Inc.Republic of Korea
United Douglas Pharm Philippines, Inc.
DR-XY46600
Nov 22, 2029
LumemoxMoxifloxacin (as hydrochloride)
5 mg/mL (0.5% w/v) Sterile Ophthalmic Solution (Eye Drops)5 mL LDPE Bottle Box of 1's
Rx
Axa Parenterals LimitedIndia
Brady Pharma Inc.
DRP-9661
Apr 23, 2031
MicromoxMoxifloxacin ( as hydrochloride )
5 mg/mL ( 0.5% w/v) Ophthalmic Solution ( Eye Drops )5mL ( net content ) in 5 mL Low Density Polyethylene ( LDPE ) screw type neck bottle with translucent cone shaped LDPE open nozzle and white High Density Polyethylene ( HDPE ) screw cap Box of 1's
Rx
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DR-XY46508
Jan 24, 2029
MilfloxMoxifloxacin (as hydrochloride)
5 mg/mL (0.5% w/v) Sterile Ophthalmic SolutionLDPE Dropper Bottle with HDPE pilfer-proof cap x 5 mL (Box of 1's)
Rx
Sun Pharmaceutical Medicare LimitedIndia
Sun Pharma Philippines, Inc.Trader: Sun Pharmaceutical Industries Ltd.
DRP-8603
Aug 2, 2028
Mo-FlorenMoxifloxacin (as hydrochloride)
5 mg per mL (0.5% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE Plastic Bottle x 5 mL with Natural LDPE Nozzle and White HDPE Cap (Box of 1's)
Rx
Indoco Remedies LimitedIndia
Ambica International Corporation
DRP-7692
Feb 7, 2028
MoflodexMoxifloxacin (As Hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)5 mL capacity White opaque LDPE Plastic Bottle with White LDPE Nozzle and White LDPE Cap x 3 mL (Box of 1's)
Rx
Pt. Ferron Par PharmaceuticalsIndonesia
Glorious Dexa Mandaya, Inc.
DRP-18473
Jul 21, 2031
Mosi Eye DropsMoxifloxacin Hydrochloride
5 mg/mL (0.5% w/w) Ophthalmic Solution (Eye Drops)5 mL LDPE Dropper Bottle (Box of 1's)
Rx
FDC LIMITED INC.India
Penta Labs Australia (Philippines)
DRP-10768
Nov 18, 2026
MoxeteroMoxifloxacin (as hydrochloride)
400 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Hetero Labs Limited (Unit V)India
Camber Pharmaceuticals, Inc.
DRP-6896
Mar 12, 2027
MoxflakemMoxifloxacin (as hydrochloride)
5 mg / mL (0.5 % w/v) Ophthalmic SolutionLDPE Dropper Bottle Sealed with White HDPE Screw Cap x 5 mL (Box of 1’s)
Rx
Beximco Pharmaceuticals Ltd.Bangladesh
Sankem Healthcare Inc.Importer: Ambica International Corporation
DRP-13374-01
Feb 8, 2028
MoxflozMoxifloxacin (as Hydrochloride)
5 mg / mL (0.5% w/v) Sterile Ophthalmic Solution5 mL white opaque LDPE bottle, white opaque LDPE nozzle and white opaque HDPE cap (Box of 1's)
Rx
Indiana OphthalmicsIndia
Ophtha Pharma Traders Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13587-01
Mar 14, 2028
MoxflozMoxifloxacin (as hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic SolutionLDPE Bottle with nozzle and cap x 5 ml (Box of 1's)
Rx
Makcur Laboratories LimitedIndia
Ophtha Pharma Traders Inc.Importer: Afree Pharmaceutical Distribution Corp.
DRP-13578-05
Mar 13, 2028
MoxianaMoxifloxacin (as Hydrochloride)
5 mg/g (0.5% w/w) Ophthalmic OintmentAluminum tube x 5 g (Box of 1's)
Rx
Indiana OphthalmicsIndia
Aglobal Care Inc.Importer: Aglobal Care, Inc.
DRP-13478
Feb 27, 2028
MoxiDenMoxifloxacin (as Hydrochloride)
5mg/mL (0.5% w/v) Ophthalmic Solution5ml LDPE Bottle with Nozzle and Cap (Box of 1's)
Rx
Makcur Laboratories Ltd.India
D&M Pharma Corp.Importer: Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Ltd.
DRP-11229-01
Apr 1, 2027
MoxidinMoxifloxacin (as hydrochloride)
5 mg per mL (0.5% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE Plastic Bottle x 5mL with Natural LDPE Nozzle and White HDPE Cap (Box of 1’s)
Rx
Indoco Remedies LimitedIndia
Medchoice Vision Care Inc.Importer: Ambica International Corporation
DRP-7692-02
Feb 7, 2028
MoxidinMoxifloxacin (as hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic SolutionLDPE bottle with HDPE cap (Box of 1's)
Rx
Hanlim Pharm. Co., Ltd.Republic of Korea
Medchoice Vision Care Inc.Importer: JLT Pharma Inc.
DRP-11720-01
Apr 22, 2027
MoxidinMoxifloxacin (as hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic Solution5 mL LDPE Bottle with nozzle and cap (Box of 1's)
Rx
Makcur Laboratories LimitedIndia
Medchoice Vision Care Inc.Importer: Afree Pharmaceutical Distribution Corp.
DRP-13578-03
Mar 13, 2028
MoxidropMoxifloxacin (as Hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)15 mL LDPE Bottle (10 mL net content) with white plug and white cap (Box of 1's)
Rx
Skymap Healthcare Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-14791
Jan 9, 2029
Moxif EyeMoxifloxacin (as Hydrochloride).
5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)LDPE Vial Sealed with HDPE Cap and LDPE Nozzle x 5 mL (Box of 1's).
Rx
East African (India) OverseasIndia
Airlife International Trading Corporation
DRP-15646
Aug 14, 2029
MoxifloMoxifloxacin (as hydrochloride)
1.6 mg/mL (400 mg/250 mL) Solution for Intravenous Infusion300 mL-capacity USP Type II transparent glass bottle containing 250 mL (net content) with rubber stopper and aluminum cap (Box of 1’s)
Rx
Sui Guan Chem. Ind. Co., Ltd.Taiwan
Caan Pharmaceutical Co., Inc.
DRP-12149
Jun 21, 2027
MoxiflostadMoxifloxacin
400mg (equivalent to 436.80mg Moxifloxacin hydrochloride) Film-Coated TabletAlu / PVC-PVDC Blister Pack x 5's (Box of 5's)
Rx
Hemofarm A.D.Serbia
Stada Philippines Inc.Trader: Stada Arzneimittel AG
DRP-11513
Mar 30, 2027
MoxiflovicMoxifloxacin (as Hydrochloride)
400 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 20’s)
Rx
XL Laboratories Pvt. Ltd.India
Guimhealth Pharmaceutical Distributor and DrugstoreImporter: Ambica International Corporation
DRP-8575-01
Jul 23, 2031
MoxifloxMoxifloxacin (as hydrochloride)
400 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's)
Rx
Lloyd Laboratories, Inc.Philippines
Randril International Co., Inc.Trader: Totalcare Pharma Inc.
DRP-15314
Jul 26, 2031
MoxifloxMoxifloxacin hydrochloride
400 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-5432
Oct 23, 2029
MoxiforceMoxifloxacin (as Hydrochloride)
5 mg/mL (0.5%w/v) Ophthalmic SolutionLDPE bottle with HDPE cap (Box of 1's )
Rx
Hanlim Pharm. Co., Ltd.Korea
JLT Pharma, Inc.
DRP-11720
Apr 22, 2027
MoxileeMoxifloxacin (as hydrochloride)
400 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Lee Pharma LimitedIndia
Aglobal Care, Inc.
DRP-14398
Aug 31, 2028
MoximaxMoxifloxacin (as hydrochloride)
5mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)LDPE Bottle with White Screw Cap x 5mL (Box of 1’s)
Rx
Makers Laboratories LtdIndia
Blue Global (FZE)
DRP-18137
May 13, 2031
MoxiquinMoxifloxacin (as hydrochloride)
400 mg/100 mL Solution for IV InfusionLDPE Bottle with Helmet Cap on Topped Bagged in Polypouch x 100 mL (Box of 1's)
Rx
BML Parenteral DrugsIndia
Triple Tact Import & Export Corp.Trader: Alwin DMD Pharmaceuticals
DRP-15418
Jul 5, 2029
MoxisaphMoxifloxacin (As Hydrochloride)
5 mg/mL (0.5% w/w) Sterile Ophtahlmic SolutionWhite HDPE Dropper Bottle with Close Nozzle and Single Pilfer Proof ring cap x 5 mL (Box of 1's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-13164
Dec 13, 2027
MoxivellMoxifloxacin (as hydrochloride)
400 mg Film-Coated CapletAluminum foil strip x 10's (Box of 10's)
Rx
PT. Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY47063
Sep 23, 2031
Moxiwar 400Moxifloxacin hydrochloride
400 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 7's (Box of 7's)
Rx
Aurobindo Pharma Limited-Unit VIIIndia
AAA Pharma, Inc.
DR-XY47907
Apr 6, 2027
MoxopthaMoxifloxacin (as hydrochloride)
5 mg/g (0.5% w/w) Sterile Ophthalmic OintmentAluminum Collapsible Tube x 5 g (Box of 1's)
Rx
Indiana OphthalmicsIndia
Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-17394
Dec 10, 2030
MoxxilMoxifloxacin (as hydrochloride)
400 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-14614
Oct 27, 2028
NoneMoxifloxacin (as hydrochloride)
400 mg Film-coated tabletAlu/Alu Blister Pack of 5 tablets (Box of 5 tablets)
Rx
Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan
AAA Pharma, Inc.
DR-XY45835
Mar 27, 2027
NoneMoxifloxacin (as hydrochloride)
400 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 20’s)
Rx
XL Laboratories Pvt. Ltd.India
International Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-8575
May 25, 2031
NoneMoxifloxacin (as Hydrochloride)
5 mg / mL (0.5 % w/v) Ophthalmic SolutionWhite LDPE Dropper Bottle with HDPE Tamper-Evident Screw Cap x 5 mL (Box of 1’s)
Rx
Beximco Pharmaceuticals Ltd.Bangladesh
Ritemed Phils., Inc.Importer: Aglobal Care
DRP-11536-01
Oct 24, 2027
NoneMoxifloxacin (as hydrochloride)
5 mg / mL (0.5 % w/v) Ophthalmic Solution5 mL LDPE Bottle with nozzle and cap (Box of 1's)
Rx
Makcur Laboratories LimitedIndia
Celsus Pharmaceuticals Phils., Inc.Importer: Afree Pharmaceutical Distribution Corp.
DRP-13578-01
Mar 13, 2028
OcumoxMoxifloxacin (as hydrochloride)
5 mg/g Sterile Ophthalmic OintmentAluminum Collapsible Tube x 3.5g (Box of 1's)
Rx
Remington Pharmaceutical industries (Pvt.) Ltd.Pakistan
Ophthamed Pharma Corp.
DRP-12248
Mar 19, 2030
OcumoxMoxifloxacin Hydrochloride
5mg/mL Sterile Ophthalmic SolutionLow Density Polyethylene (LDPE) Plastic Vial with Dropping Nozzle and Hard PVC Cap x 5 mL Box of 1's
Rx
Remington Pharmaceutical industries (Pvt.) Ltd.Pakistan
OPHTHAMED PHARMA CORP.
DRP-12277
Oct 11, 2028
OflokasinMoxifloxacin
400mg/ 250mL Solution for Infusion250mL Type II Glass bottle with grey rubber stopper and aluminum cap with flip-off seal (Box of 1's)
Rx
Anfarm Hellas S.A.Greece
Saifen Drugs Philippines Inc.
DRP-16862
Jul 30, 2030
OpmoxinMoxifloxacin (as Hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic SolutionWhite LDPE Dropper Bottle with HDPE Tamper-Evident Screw Cap X 5 mL (Box of 1’s)
Rx
Beximco Pharmaceuticals Ltd.Bangladesh
Aglobal Care, Inc.
DRP-11536
Oct 24, 2027
OpthomoxMoxifloxacin (as Hydrochloride)
5 mg/mL (0.5% w/v) Sterile Ophthalmic Solution.5 mL white opaque LDPE bottle, white opaque LDPE nozzle and white opaque HDPE cap (Box of 1's)
Rx
Indiana OphthalmicsIndia
Medinova Pharmaceutical Inc.
DRP-13587
Mar 14, 2028
OptimoxMoxifloxacin (as hydrochloride)
5 mg/mL (0.5%) Ophthalmic Solution (Eye Drops)White Opaque LDPE Plastic Dropper Bottle x 5 mL with white Opaque HDPE Plastic cap (Box of 1's)
Rx
Aristopharma Ltd.Bangladesh
Sahar International Trading Inc.
DRP-6998
May 18, 2031
OptiwellMoxifloxacin (as hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic Solution5 mL LDPE vial with LDPE nozzle and white HDPE cap (Box of 1's)
Rx
Indoco Remedies Limited Plant IIIndia
Despina Pharma Inc.
DRP-14889
Jan 31, 2029
PlaxomibMoxifloxacin (as Hydrochloride)
5 mg/mL (0.5% 0.5% w/v) Ophthalmic SolutionLDPE Dropper Bottle Sealed with White HDPE Screw Cap x 5 mL (Box of 1's)
Rx
Beximco Pharmaceuticals Ltd.Bangladesh
Ambica International Corporation
DRP-13374
Feb 8, 2028
Pol-MoxiMoxifloxacin (as hydrochloride)
400 mg/ 250 mL Solution for I.V. Infusion250 mL Polypropylene bag with SFC port and SFC cap (Box of 1's)
Rx
Polifarma Ilac San Ve. Tic. A.S.Turkey
Endure Medical Inc.
DR-XY48663
Mar 22, 2028
QuinoftaMoxifloxacin (as hydrochloride)
5 mg per mL (0.5% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE Plastic Bottle x 5 mL with Natural LDPE Nozzle and White HDPE Cap (Box of 1’s)
Rx
Indoco Remedies LimitedIndia
Ophthamed Pharma Corp.Importer: Ambica International Corporation
DRP-7692-01
Feb 7, 2028
SensomoxMoxifloxacin (as hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic Solution5 mL LDPE Bottle with nozzle and cap (Box of 1's)
Rx
Makcur Laboratories LimitedIndia
Sensorycare Pharma Co.Importer: Afree Pharmaceutical Distribution Corp.
DRP-13578-04
Mar 13, 2028
SvozMoxifloxacin (as hydrochloride)
5 mg/mL (0.5% w/v) Ophthalmic SolutionWhite Opaque LDPE Plastic Bottle with Eye Tip and Pale Blue HDPE Plastic Screw Cap x 5 mL (Box of 1's)
Rx
Siam Bheasach Co., Ltd.Thailand
Endure Medical, IncTrader: Siampharmaceutical Co.,
DR-XY49231
Sep 25, 2029
VeloxinMoxifloxacin (as Hydrochloride)
400 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's)
Rx
Pacific Pharmaceuticals LimitedPakistan
Raquel Abbas Pharma Inc.
DRP-15567
Aug 2, 2029
ViasynMoxifloxcinVariant spelling
5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)LDPE White Bottle with HDPE White Cap x 5 ML (Box of 1's)
Rx
Laboratorios Ashford L.D.A.China
Marrion Pharma Inc.
DR-XY49789
Sep 3, 2031
VigamoxMoxifloxacin (As Hydrochloride)
5 mg/mL (0.5% w/v) Sterile Ophthalmic Solution5 mL in LDPE Plastic Bottle (droptainer) (box of 1's)
Rx
Alcon-Couvreur NVBelgium
Novartis Healthcare Philippines, Inc.
DR-XY30956
Jun 20, 2028
VistamoxMoxifloxacin Hydrochloride
5 mg/mL (0.50% w/v) Ophthalmic Solution (Drops)5 mL net volume in White LDPE Plastic Bottle with White LDPE Nozzle and White HDPE Cap x 10 mL (Box of 1’s)
Rx
EL Laboratories, Inc.Philippines
Trader: Vista Pharma, Inc.
DR-XY42590
Oct 7, 2030
XifloxMoxifloxacin Hydrochloride
1.6 mg/ mL (400 mg / 250 mL) Solution for Injection (IV Infusion)USP Type II Clear Glass Vial with grey rubber stopper and blue flip-off seal (Box of 1’s)
Rx
Getz Pharma (Pvt.), Ltd.Pakistan
Importer: Getz Pharma (Phils.), Inc.
DR-XY44737
Aug 4, 2031
XifloxMoxifloxacin (as hydrochloride)
400mg Film-Coated TabletAlu/Alu Blister Pack x 5's (Box of 5's)
Rx
Getz Pharma Pvt. Ltd.Pakistan
Getz Pharma (Phils.), Inc.
DR-XY48624
Feb 14, 2028
(no brand name)Moxifloxacin (as hydrochloride)
400mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 100's)
Rx
Lupin LimitedIndia
Lupin Philippines, Inc.
DR-XY48994
Jan 31, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Ophthalmic solution containing moxifloxacin 0.5%. Ophthalmic solution containing moxifloxacin 0.5%. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Hypersensitivity Reactions: Hypersensitivity and anaphylaxis have been reported with systemic use of moxifloxacin. (5.1)
  • Prolonged Use: May result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. (5.2)
  • Avoid Contact Lens Wear: Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis. (5.3)
5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching.

If an allergic reaction to moxifloxacin occurs, discontinue use of the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.

5.2 Growth of Resistant Organisms With Prolonged Use

5.2 Growth of Resistant Organisms With Prolonged Use As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.

5.3 Avoidance of Contact Lens Wear

5.3 Avoidance of Contact Lens Wear Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with VIGAMOX ®. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing.

These events occurred in approximately 1%-6% of patients. Nonocular adverse events reported at a rate of 1%-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis. The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing.

These events occurred in approximately 1% to 6% of patients. (6) To report SUSPECTED ADVERSE REACTIONS, contact Harrow Eye, LLC at 844-446-6979 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with VIGAMOX ® in pregnant women to inform any drug-associated risks. Oral administration of moxifloxacin to pregnant rats and monkeys and intravenously to pregnant rabbits during the period of organogenesis did not produce adverse maternal or fetal effects at clinically relevant doses.

Oral administration of moxifloxacin to pregnant rats during late gestation through lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses (see Data). Data Animal Data Embryo-fetal studies were conducted in pregnant rats administered with 20, 100, or 500 mg/kg/day moxifloxacin by oral gavage on Gestation Days 6 to 17, to target the period of organogenesis.

Decreased fetal body weight and delayed skeletal development were observed at 500 mg/kg/day [277 times the human area under the curve (AUC) at the recommended human ophthalmic dose]. The No-Observed-Adverse-Effect-Level (NOAEL) for developmental toxicity was 100 mg/kg/day (30 times the human AUC at the recommended human ophthalmic dose).

Embryo-fetal studies were conducted in pregnant rabbits administered with 2, 6.5, or 20 mg/kg/day moxifloxacin by intravenous administration on Gestation Days 6 to 20, to target the period of organogenesis. Abortions, increased incidence of fetal malformations, delayed fetal skeletal ossification, and reduced placental and fetal body weights were observed at 20 mg/kg/day (1086 times the human AUC at the recommended human ophthalmic dose), a dose that produced maternal body weight loss and death.

The NOAEL for developmental toxicity was 6.5 mg/kg/day (246 times the human AUC at the recommended human ophthalmic dose). Pregnant cynomolgus monkeys were administered moxifloxacin at doses of 10, 30, or 100 mg/kg/day by intragastric intubation between Gestation Days 20 and 50, targeting the period of organogenesis. At the maternal toxic doses of ≥ 30 mg/kg/day, increased abortion, vomiting, and diarrhea were observed.

Smaller fetuses/reduced fetal body weights were observed at 100 mg/kg/day (2864 times the human AUC at the recommended human ophthalmic dose). The NOAEL for fetal toxicity was 10 mg/kg/day (174 times the human AUC at the recommended human ophthalmic dose). In a pre- and postnatal study, rats were administered moxifloxacin by oral gavage at doses of 20, 100, and 500 mg/kg/day from Gestation Day 6 until the end of lactation.

Maternal death occurred during gestation at 500 mg/kg/day. Slight increases in the duration of pregnancy, reduced pup birth weight, and decreased prenatal and neonatal survival were observed at 500 mg/kg/day (estimated 277 times the human AUC at the recommended human ophthalmic dose). The NOAEL for pre- and postnatal development was 100 mg/kg/day (estimated 30 times the human AUC at the recommended human ophthalmic dose).

Mechanism of action

12.1 Mechanism of Action Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs [see Microbiology (12.4)].

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The plasma half-life of moxifloxacin was estimated to be 13 hours.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of VIGAMOX ® 3 times a day. The mean steady-state C max (2.7 ng/mL) and AUC 0-∞ (41.9 ng●hr/mL) values were 1600 and 1100 times lower than the mean C max and AUC reported after therapeutic 400 mg doses of moxifloxacin. The plasma half-life of moxifloxacin was estimated to be 13 hours.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Moxifloxacin 5 mg/mL, 5 mL Ophthalmic Solution₱320.00–₱493.00Reference ₱493.00per unitDPRI procurement range
Moxifloxacin (as Hydrochloride) 400 mg Film coated tablet₱71.20–₱103.67Reference ₱71.20per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Moxifloxacin
PNF listingOral: 400 mg film coated tablet
PNF listingOphthalmic solution: 5 mg/mL (0.5% w/v) sterile ophthalmic solution, 5 mL bottle (as hydrochloride)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. VIGAMOX · Harrow Eye, LLC [US FDA-approved label, version 4, January 22, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12053b08-7e66-c6f3-e063-6394a90a9cd9
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .